Literature DB >> 2563292

Neuronal uptake and metabolism of 2- and 6-fluorodopamine: false neurotransmitters for positron emission tomographic imaging of sympathetically innervated tissues.

G Eisenhofer1, D Hovevey-Sion, I J Kopin, R Miletich, K L Kirk, R Finn, D S Goldstein.   

Abstract

The neuronal uptake and metabolism of 2-fluorodopamine (2F-dopamine), 6-fluorodopamine (6F-dopamine) and tritium-labeled dopamine were compared in heart, submaxillary gland and spleen of rats to assess the utility of 18F-labeled 2F- or 6F-dopamine for positron emission tomographic imaging of sympathetically innervated tissues. Tritiated dopamine with and without 2F- or 6F-dopamine, or tritiated 2F-dopamine alone, were injected i.v. into rats that were or were not pretreated with desipramine to block catecholamine neuronal uptake or with reserpine to block vesicular translocation of catecholamines. Tissue and plasma samples were obtained at intervals up to 1 hr after injections. At 1 hr after injection of tritiated dopamine, tritium-labeled norepinephrine, dopamine, dihydroxyphenylacetic acid and dihydroxyphenylglucol accounted for less than 2% of the tritium in plasma but up to 92% of that in tissues; tritiated norepinephrine accounted for 70% or more of the tritium in tissues. In contrast, at 1 hr after injection of tritiated 2F-dopamine, tritiated 2F-norepinephrine accounted for 30 to 46% of the tritium in tissues. Desipramine and reserpine pretreatment blocked the tissue accumulation of tritiated and fluorinated dopamine as well as their dihydroxy-metabolites, indicating that accumulation of exogenous norepinephrine and dopamine analogs was within sympathetic storage vesicles. Relative to the doses of dopamine precursors, less 2F- and 6F-norepinephrine accumulated in tissues than tritiated norepinephrine, due largely to inefficient beta-hydroxylation of fluorinated dopamine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2563292

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Authors:  Lucia Martiniova; Shiromi M Perera; Frederieke M Brouwers; Salvatore Alesci; Mones Abu-Asab; Amanda F Marvelle; Dale O Kiesewetter; David Thomasson; John C Morris; Richard Kvetnansky; Arthur S Tischler; James C Reynolds; Antonio Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

2.  Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma.

Authors:  Lucia Martiniova; Susannah Cleary; Edwin W Lai; Dale O Kiesewetter; Jurgen Seidel; Linda F Dawson; Jacqueline K Phillips; David Thomasson; Xiaoyuan Chen; Graeme Eisenhofer; James F Powers; Richard Kvetnansky; Karel Pacak
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

3.  Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes.

Authors:  Ingo Janssen; Clara C Chen; Zhenping Zhuang; Corina M Millo; Katherine I Wolf; Alexander Ling; Frank I Lin; Karen T Adams; Peter Herscovitch; Richard A Feelders; Antonio T Fojo; David Taieb; Electron Kebebew; Karel Pacak
Journal:  J Nucl Med       Date:  2017-03-23       Impact factor: 10.057

4.  Efficient automated syntheses of high specific activity 6-[18F]fluorodopamine using a diaryliodonium salt precursor.

Authors:  Kiel D Neumann; Linlin Qin; Amy L Vāvere; Bin Shen; Zheng Miao; Frederick T Chin; Barry L Shulkin; Scott E Snyder; Stephen G DiMagno
Journal:  J Labelled Comp Radiopharm       Date:  2015-12-23       Impact factor: 1.921

5.  Novel electrophilic synthesis of 6-[¹⁸F]fluorodopamine and comprehensive biological evaluation.

Authors:  Olli Eskola; Tove J Grönroos; Alexandru Naum; Päivi Marjamäki; Sarita Forsback; Jörgen Bergman; Sami Länkimäki; Jan Kiss; Timo Savunen; Juhani Knuuti; Merja Haaparanta; Olof Solin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-10       Impact factor: 9.236

6.  Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases.

Authors:  David S Goldstein; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

7.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Rachel Sullivan; Daniel J Gross; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2012-10-25       Impact factor: 5.372

8.  Regional distribution and kinetics of [18F]6-flurodopamine as a measure of cardiac sympathetic activity in humans.

Authors:  G Coates; R Chirakal; E L Fallen; G Firnau; E S Garnett; M V Kamath; A Scheffel; C Nahmias
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

9.  Pioneer Award Address: ignorance isn't biased: comments on receiving the Pioneer Award.

Authors:  David S Goldstein
Journal:  Cleve Clin J Med       Date:  2009-04       Impact factor: 2.321

Review 10.  Vesicular integrity in Parkinson's disease.

Authors:  Shawn P Alter; Gina M Lenzi; Alison I Bernstein; Gary W Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.